ES2979068T3 - Anticuerpos para anti-claudina 18A2 y utilización de los mismos - Google Patents

Anticuerpos para anti-claudina 18A2 y utilización de los mismos Download PDF

Info

Publication number
ES2979068T3
ES2979068T3 ES17823694T ES17823694T ES2979068T3 ES 2979068 T3 ES2979068 T3 ES 2979068T3 ES 17823694 T ES17823694 T ES 17823694T ES 17823694 T ES17823694 T ES 17823694T ES 2979068 T3 ES2979068 T3 ES 2979068T3
Authority
ES
Spain
Prior art keywords
antibody
cell
cells
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17823694T
Other languages
English (en)
Spanish (es)
Inventor
Peng Wang
Hua Jiang
Linlin Yang
Zhimin Shi
Huamao Wang
Zonghai Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crage Medical Co Ltd
Original Assignee
Crage Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Crage Medical Co Ltd filed Critical Crage Medical Co Ltd
Application granted granted Critical
Publication of ES2979068T3 publication Critical patent/ES2979068T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES17823694T 2016-07-08 2017-07-10 Anticuerpos para anti-claudina 18A2 y utilización de los mismos Active ES2979068T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610536449 2016-07-08
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法
PCT/CN2017/092381 WO2018006882A1 (zh) 2016-07-08 2017-07-10 抗密蛋白18a2的抗体及其应用

Publications (1)

Publication Number Publication Date
ES2979068T3 true ES2979068T3 (es) 2024-09-24

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17823694T Active ES2979068T3 (es) 2016-07-08 2017-07-10 Anticuerpos para anti-claudina 18A2 y utilización de los mismos

Country Status (13)

Country Link
US (2) US11111295B2 (esLanguage)
EP (1) EP3483182B1 (esLanguage)
JP (1) JP7587921B2 (esLanguage)
KR (1) KR102723896B1 (esLanguage)
CN (1) CN109790222B (esLanguage)
AU (1) AU2017294276B2 (esLanguage)
BR (1) BR112019000327A8 (esLanguage)
CA (1) CA3030257A1 (esLanguage)
CL (1) CL2019000061A1 (esLanguage)
ES (1) ES2979068T3 (esLanguage)
IL (1) IL264144B2 (esLanguage)
SG (1) SG11201900171QA (esLanguage)
WO (1) WO2018006882A1 (esLanguage)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030257A1 (en) * 2016-07-08 2018-01-11 Carsgen Therapeutics Co., Ltd. Antibody for anti-claudin 18a2 and use thereof
WO2019149279A1 (zh) 2018-02-02 2019-08-08 科济生物医药（上海）有限公司 细胞免疫治疗的组合
KR102784161B1 (ko) * 2018-03-08 2025-03-19 페인스 테라퓨틱스 인코포레이티드 항-클라우딘 18.2 항체 및 이의 용도
CN119770648A (zh) * 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
EP3765522A4 (en) * 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
EP3789486A4 (en) * 2018-05-03 2022-03-30 Cafa Therapeutics Limited MANIPULATED IMMUNE EFFECTOR CELLS AND USE THEREOF
KR20210018838A (ko) 2018-05-15 2021-02-18 카르스젠 테라퓨틱스 컴퍼니, 리미티드 유전자 조작된 세포 및 응용
KR20220103820A (ko) * 2018-05-18 2022-07-22 라노바 메디신즈 리미티드 컴파니 항-클라우딘 18.2 항체 및 이의 사용
WO2020020210A1 (zh) 2018-07-24 2020-01-30 科济生物医药（上海）有限公司 免疫效应细胞治疗肿瘤的方法
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
US20220119517A1 (en) * 2018-08-27 2022-04-21 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-claudin18.2 antibody and use thereof
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
JP2022517301A (ja) 2018-12-07 2022-03-08 カファ セラピューティクス リミテッド 腫瘍併用免疫療法
CA3122135A1 (en) * 2018-12-07 2020-06-11 Zlip Holding Limited Anti-claudin antibodies and uses thereof
MX2021007939A (es) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
US12297265B2 (en) 2018-12-28 2025-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
KR20210126008A (ko) 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
CN111434692B (zh) * 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP2022523749A (ja) * 2019-02-01 2022-04-26 クレージュ メディカル カンパニー，リミテッド Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞
AU2020217012A1 (en) 2019-02-01 2021-08-19 CSPC Megalith Biopharmaceutical Co., Ltd. Anti-claudin 18 antibodies and methods of use thereof
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN120944827A (zh) * 2019-03-27 2025-11-14 宾夕法尼亚大学董事会 Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
CN113784980B (zh) * 2019-03-29 2024-04-30 凡恩世制药(北京)有限公司 人源化抗Claudin18.2嵌合抗原受体及其用途
TWI848090B (zh) * 2019-04-01 2024-07-11 大陸商江蘇恆瑞醫藥股份有限公司 密蛋白抗體及其應用
WO2020211792A1 (zh) * 2019-04-19 2020-10-22 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用
CN113825771B (zh) 2019-05-16 2024-02-09 齐鲁制药有限公司 针对密蛋白18a2的抗体及其应用
JP7600218B2 (ja) * 2019-05-24 2024-12-16 サンヨウ バイオファーマシューティカルズ カンパニー リミテッド 新規なｃｌｄｎ１８．２結合分子
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
BR112021023897A2 (pt) * 2019-05-30 2022-01-25 Shandong Boan Biotechnology Co Ltd Anticorpo ou receptor de antígeno quimérico que visa claudina18.2
KR102777693B1 (ko) * 2019-07-17 2025-03-07 더 리전트 오브 더 유니버시티 오브 캘리포니아 Claudin18 항체 및 암 치료 방법
BR112021008870A2 (pt) * 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
MY209779A (en) * 2019-11-05 2025-08-04 Lanova Medicines Ltd Antibody-drug conjugates targeting claudin 18.2
CN115666594A (zh) * 2019-11-29 2023-01-31 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
WO2021111003A1 (en) 2019-12-06 2021-06-10 SOTIO a.s. Humanized cldn18.2 antibodies
CN114901365B (zh) 2019-12-23 2025-07-15 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体
CA3166498A1 (en) * 2020-01-03 2021-07-08 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
US20230096452A1 (en) * 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
EP4110820A4 (en) * 2020-02-25 2024-03-27 Gensun Biopharma Inc. TRISPECIFIC T CELL CONTACTING AGENTS
MX2022014332A (es) * 2020-05-15 2022-12-13 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo.
EP4169947A4 (en) * 2020-06-19 2024-11-06 Innovent Biologics (Singapore) Pte. Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND USE THEREOF
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
WO2022028623A1 (zh) 2020-08-07 2022-02-10 佧珐药业有限公司 工程化改造的细胞以及工程化改造细胞的方法
KR20230078701A (ko) * 2020-09-30 2023-06-02 난징 진스크립트 바이오테크 컴퍼니 리미티드 인간 클라우딘 18.2를 표적화하는 항체 및 이의 용도
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CN116635085A (zh) 2020-12-23 2023-08-22 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体-药物缀合物
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
JP2024514246A (ja) * 2021-04-02 2024-03-29 オリセル セラピューティクス カンパニー リミテッド Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
CN117545771A (zh) 2021-04-08 2024-02-09 克莱格医学有限公司 细胞免疫治疗的应用
CN117480247A (zh) * 2021-04-15 2024-01-30 恺兴生命科技(上海)有限公司 嵌合t细胞受体及其应用
US20250269028A1 (en) 2021-06-29 2025-08-28 Carsgen Therapeutics Co., Ltd Chimeric polypeptide for regulating cell physiological activity
CN114751984B (zh) * 2021-09-03 2023-02-14 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
EP4428154A1 (en) * 2021-11-05 2024-09-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-cldn18.2 antibody and use thereof
WO2023213280A1 (zh) * 2022-05-06 2023-11-09 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
US20260028422A1 (en) * 2022-07-28 2026-01-29 Concept To Medicine Biotech Co., Ltd. Anti-MerTK ANTIBODIES AND USES THEREOF
EP4562134A1 (en) 2022-07-29 2025-06-04 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN118873678A (zh) 2023-01-18 2024-11-01 泰励生物科技（上海）有限公司 抗体偶联药物及其用途
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105315375B (zh) * 2014-07-17 2021-04-23 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CR20180348A (es) 2015-12-04 2018-08-23 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-claudina y sus métodos de uso
CN118146379B (zh) * 2016-04-26 2025-09-09 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
CA3030257A1 (en) * 2016-07-08 2018-01-11 Carsgen Therapeutics Co., Ltd. Antibody for anti-claudin 18a2 and use thereof
CN119770648A (zh) * 2018-03-09 2025-04-08 克莱格医学有限公司 用于治疗肿瘤的方法和组合物
KR20210072027A (ko) * 2018-09-30 2021-06-16 카파 테라퓨틱스 리미티드 Cldn18의 항체 및 화학요법 약물의 병용 요법
KR20210126008A (ko) * 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
CN116348604A (zh) * 2020-08-10 2023-06-27 克莱格医学有限公司 多功能的免疫效应细胞及其应用

Also Published As

Publication number Publication date
US11111295B2 (en) 2021-09-07
KR102723896B1 (ko) 2024-11-01
CA3030257A1 (en) 2018-01-11
EP3483182A1 (en) 2019-05-15
CN109790222B (zh) 2022-03-15
SG11201900171QA (en) 2019-02-27
CL2019000061A1 (es) 2019-05-03
BR112019000327A2 (pt) 2019-08-13
IL264144B1 (en) 2023-07-01
JP7587921B2 (ja) 2024-11-21
CN109790222A (zh) 2019-05-21
JP2019531084A (ja) 2019-10-31
KR20190038564A (ko) 2019-04-08
BR112019000327A8 (pt) 2022-10-18
RU2019101430A (ru) 2020-08-10
US20220185880A1 (en) 2022-06-16
RU2019101430A3 (esLanguage) 2021-05-17
IL264144B2 (en) 2023-11-01
AU2017294276B2 (en) 2024-08-01
NZ750420A (en) 2025-06-27
EP3483182A4 (en) 2020-07-29
US20190233511A1 (en) 2019-08-01
AU2017294276A1 (en) 2019-02-28
WO2018006882A1 (zh) 2018-01-11
EP3483182B1 (en) 2024-05-08
IL264144A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
ES2979068T3 (es) Anticuerpos para anti-claudina 18A2 y utilización de los mismos
JP7397840B2 (ja) Ｃｄ２０免疫療法のための組成物および方法
ES3035979T3 (en) Bcma-targeting antibody and use thereof
ES2891332T3 (es) Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
ES2781175T3 (es) Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
ES2923397T3 (es) Tratamiento del cáncer utilizando un receptor de antígeno quimérico anti-CD19 humanizado
ES3009008T3 (en) Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
ES2948133T3 (es) Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
ES2828982T3 (es) Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
US20140099309A1 (en) Use of a Trans-Signaling Approach in Chimeric Antigen Receptors
US11530270B2 (en) Antibody targeting IL-13RA2 and use thereof
US20240247070A1 (en) Compositions and methods for t-cell and cytokine activation
US20260007747A1 (en) Engineered PD-L1-Targeting Gamma Delta T Cell Receptors
WO2018149358A1 (zh) 靶向il-13ra2的抗体及其应用
CN119421892A (zh) 靶向Siglec-7的双特异性自然杀伤接合子
RU2793445C2 (ru) Антитело против клаудина 18а2 и его применение
HK40002280B (zh) 抗密蛋白18a2的抗体及其应用
US20230295564A1 (en) Galectin-9 Specific Binding Agents for Use in Treating Cancer
HK40002280A (zh) 抗密蛋白18a2 的抗体及其应用
HK40017077A (en) Il-13ra2-targeted antibody and application thereof